Tempest Therapeutics special meeting adjourned after proposal fell short of 75% vote threshold

• Tempest Therapeutics held a reconvened special shareholder meeting on Sept. 15, 2026 to vote on a charter amendment.
• The amendment would remove specified supermajority voting requirements, permit shareholder action by written consent.
• Shareholders did not approve the amendment at the meeting, leaving the charter unchanged.
• The meeting was adjourned, set to reconvene on Oct. 14, 2026 for another vote on the same amendment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-393151), on September 16, 2026, and is solely responsible for the information contained therein.